Life Sciences Legislation And Regulation To Watch In 2016
Law360, New York (December 24, 2015, 8:38 PM EST) -- When legislative and regulatory activity picks up again in 2016, the federal government will have important life sciences issues on its plate, from prescription drug pricing to the 21st Century Cures Act.
But what actually gets done in the life sciences arena will be dramatically influenced by the upcoming presidential election, experts say.
Controversial laws, rules and guidances will become more difficult to finalize, as campaigning ramps up and incumbents running for re-election or a different office are less likely to take a stance that could alienate potential voters or donors. Meanwhile, other issues may see a higher likelihood of action...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!